Retatrutide, developed by Soma Chems , is gaining considerable attention as a potential method for metabolic regulation. This innovative compound integrates the mechanism of a GLP-1 receptor agonist and a GIP receptor stimulant, aiming to simply promote metabolic improvements but also address underlying metabolic factors. Early patient trials have